- Conditions
- Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
- Interventions
- Durvalumab, Yttrium-90 RadioEmbolization
- Drug · Radiation
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 593
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
- Biological · Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
- Interventions
- HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells, laboratory biomarker analysis, flow cytometry, immunoenzyme technique
- Biological · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Postdural Puncture Headache, Epidural Analgesia, Obstetric
- Interventions
- EpiZact-assisted epidural placement
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HIV Infections
- Interventions
- Sub C gp140 Vaccine, MF59C.1 Adjuvant
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Seattle Project Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
- Conditions
- Zika Virus Infection
- Interventions
- Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Kaposi Sarcoma
- Interventions
- SkinScan3D camera
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Influenza
- Interventions
- FluLaval™ Quadrivalent, Fluzone® Quadrivalent
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 2,432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
- Conditions
- Infections, Meningococcal
- Interventions
- GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
- Conditions
- Bladder Cancer
- Interventions
- Bacillus Calmette-Guerin (BCG)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Kidney Cancer
- Interventions
- NeoVax, Ipilimumab
- Drug
- Lead sponsor
- Patrick Ott, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stroke
- Interventions
- tDCS, AMT, Treadmill training
- Other · Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Drug · Device
- Lead sponsor
- Medtronic Neurovascular Clinical Affairs
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Interventions
- Not listed
- Lead sponsor
- Metro Health, Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Springfield, Illinois • Wyoming, Michigan + 3 more
- Conditions
- HIV
- Interventions
- 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Glioblastoma, Adult
- Interventions
- Multiple dose of EO2401
- Biological
- Lead sponsor
- Enterome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stroke, Hemiplegia, Hemiparesis
- Interventions
- iTBS&eCIMT
- Combination Product
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy
- Interventions
- Magstim Rapid2
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Prevention
- Interventions
- PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
- Biological
- Lead sponsor
- Worcester HIV Vaccine
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Aphasia
- Interventions
- Transcranial direct current stimulation
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes Mellitus
- Interventions
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Device
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 6 more
- Conditions
- Colonic Neoplasms
- Interventions
- FIT Outreach
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 13,470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California